Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles.

ABSTRACT:

Introduction

Blood biomarkers represent a major advance for improving the management, diagnosis, and monitoring of Alzheimer's disease (AD). However, their context of use in relation to routine cerebrospinal fluid (CSF) analysis for the quantification of amyloid peptides and tau proteins remains to be determined.

Methods

We studied in two independent cohorts, the performance of blood biomarkers in detecting "nonpathological" (A-/T-/N-), amyloid (A+) or neurodegenerative (T+ /N+) CSF profiles.

Results

Plasma Aβ_1-42/Aβ_1-40 ratio and phosphorylated tau (p-tau(181)) were independent and complementary predictors of the different CSF profile and in particular of the nonpathological (A-/T-/N-) profile with a sensitivity and specificity close to 85%. The

SUBMITTER: Delaby C 

PROVIDER: S-EPMC8866346 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature